Sean Stalfort

Sean is the President of PBM Capital where he sources and structures new investment opportunities, oversees portfolio companies and manages the daily operations of the company. He has been an investor and, on the Board/Board observer of AveXis (sold to Novartis), ArcherDx (sold to Invitae), Dova (sold to SOBI), Verrica (NASDAQ: VRCA), Taysha (NASDAQ: TSHA), and Acumen Pharmaceuticals (NASDAQ: ABOS) as well as current portfolio companies including Xalud Therapeutics, Candel Therapeutics and Lexeo Pharmaceuticals. Prior to PBM Capital, Sean was the Executive Vice President for New Business Development and M&A for PBM Products where he sourced and managed new growth opportunities internationally as well as various capital market activities through the sale of the company to Perrigo for over $800 million. Earlier in his career, Sean worked at several investment firms including Greenwich Capital Markets and CS First Boston.

Sean graduated from Brown University with a B.A. in Business Economics and Political Science.